Minimal clinically important difference for asthma endpoints: an expert consensus report
Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management. The aim of the current expert consensus report is to provide a “state-of-the-a...
Main Authors: | Matteo Bonini, Marcello Di Paolo, Diego Bagnasco, Ilaria Baiardini, Fulvio Braido, Marco Caminati, Elisiana Carpagnano, Marco Contoli, Angelo Corsico, Stefano Del Giacco, Enrico Heffler, Carlo Lombardi, Ilaria Menichini, Manlio Milanese, Nicola Scichilone, Gianenrico Senna, Giorgio W. Canonica |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2020-06-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/29/156/190137.full |
Similar Items
-
Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
by: Diego Bagnasco, et al.
Published: (2020-08-01) -
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
by: Marco Caminati, et al.
Published: (2023-02-01) -
Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
by: Diego Bagnasco, et al.
Published: (2020-08-01) -
Explainable artificial intelligence for cough-related quality of life impairment prediction in asthmatic patients.
by: Sara Narteni, et al.
Published: (2024-01-01) -
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
by: Contoli M, et al.
Published: (2016-12-01)